NBIX
Neurocrine Biosciences IncCompany with tickers: NBIX
CIK
914475
CUSIP
64125C109
Shares Outstanding
100,549,983
13F Activity (30d)
130 filings
121 filers
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Program Authorized
$500,000,000
as of 2025-02-28
Remaining Authorization
$276,300,000
as of 2026-03-31
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2026-03-31 YTD | $54,000,000 | 10-Q, filed 2026-05-05 |
| 2025-12-31 | $167,700,000 | 10-K, filed 2026-02-11 |
| 2024-12-31 | $300,000,000 | 10-K, filed 2026-02-11 |
| 2023-12-31 | $0 | 10-K, filed 2026-02-11 |
| 2022-12-31 | $0 | 10-K, filed 2025-02-10 |
Recent quarters
| Quarter Ended | Cash Spent | Source |
|---|---|---|
| 2026-03-31 | $54,000,000 | 10-Q, filed 2026-05-05 |
| 2025-12-31 | $0 Δ | 10-K, filed 2026-02-11 |
| 2025-09-30 | $0 Δ | 10-Q, filed 2025-10-28 |
| 2025-06-30 | $17,700,000 Δ | 10-Q, filed 2025-07-30 |
| 2025-03-31 | $150,000,000 | 10-Q, filed 2026-05-05 |
| 2024-12-31 | $300,000,000 Δ | 10-K, filed 2026-02-11 |
| 2024-09-30 | $0 Δ | 10-Q, filed 2025-10-28 |
| 2024-06-30 | $0 Δ | 10-Q, filed 2025-07-30 |
| 2024-03-31 | $0 | 10-Q, filed 2025-05-05 |